
Citation: Marc H V Van Regenmortel. Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?[J]. AIMS Public Health, 2015, 2(2): 183-193. doi: 10.3934/publichealth.2015.2.183
[1] | Zhouchen Lin . A Review on Low-Rank Models in Data Analysis. Big Data and Information Analytics, 2016, 1(2): 139-161. doi: 10.3934/bdia.2016001 |
[2] | Ioannis D. Schizas, Vasileios Maroulas, Guohua Ren . Regularized kernel matrix decomposition for thermal video multi-object detection and tracking. Big Data and Information Analytics, 2018, 3(2): 1-23. doi: 10.3934/bdia.2018004 |
[3] | Ming Yang, Dunren Che, Wen Liu, Zhao Kang, Chong Peng, Mingqing Xiao, Qiang Cheng . On identifiability of 3-tensors of multilinear rank (1; Lr; Lr). Big Data and Information Analytics, 2016, 1(4): 391-401. doi: 10.3934/bdia.2016017 |
[4] | Jinyuan Zhang, Aimin Zhou, Guixu Zhang, Hu Zhang . A clustering based mate selection for evolutionary optimization. Big Data and Information Analytics, 2017, 2(1): 77-85. doi: 10.3934/bdia.2017010 |
[5] | John A. Doucette, Robin Cohen . A testbed to enable comparisons between competing approaches for computational social choice. Big Data and Information Analytics, 2016, 1(4): 309-340. doi: 10.3934/bdia.2016013 |
[6] | Yaguang Huangfu, Guanqing Liang, Jiannong Cao . MatrixMap: Programming abstraction and implementation of matrix computation for big data analytics. Big Data and Information Analytics, 2016, 1(4): 349-376. doi: 10.3934/bdia.2016015 |
[7] | Xiaoxiao Yuan, Jing Liu, Xingxing Hao . A moving block sequence-based evolutionary algorithm for resource investment project scheduling problems. Big Data and Information Analytics, 2017, 2(1): 39-58. doi: 10.3934/bdia.2017007 |
[8] | Cun Chen, Hui Peng . Dynamic mode decomposition for blindly separating mixed signals and decrypting encrypted images. Big Data and Information Analytics, 2024, 8(0): 1-25. doi: 10.3934/bdia.2024001 |
[9] | Weidong Bao, Haoran Ji, Xiaomin Zhu, Ji Wang, Wenhua Xiao, Jianhong Wu . ACO-based solution for computation offloading in mobile cloud computing. Big Data and Information Analytics, 2016, 1(1): 1-13. doi: 10.3934/bdia.2016.1.1 |
[10] | Dongyang Yang, Wei Xu . Statistical modeling on human microbiome sequencing data. Big Data and Information Analytics, 2019, 4(1): 1-12. doi: 10.3934/bdia.2019001 |
As far as the built environment is concerned, improving performance implies reasoning on multiple levels and taking action on a variety of elements in a building or a building unit. The expression building performance is a broad concept with no univocal definition in the literature, possibly because constructions are durable goods and complex systems. Forasmuch as building performance is difficult to define, it is also hard to evaluate. Early examples of building performance evaluation were developed in the US between the late sixties and the mid-seventies, leading authors to use the expression post-occupancy evaluation for the methodologies meant to evaluate building performance after their construction and occupation. More recently, the academic and professional debate has further evolved, expanding the research interest in performance evaluation to the whole building life-cycle [1,2].
A broad research strand has long since focused on building performance from the perspective of energy saving and efficiency [3,4,5], especially concerning energy consumption from non-renewable sources, not least because of the implications in the matter of greenhouse gas emissions [6,7,8,9]. Over time, the research strand mentioned above branched out into several specific fields of study, some of which—among the primary ones—can be identified as follows: 1) building system optimization as well as integration of innovative technologies into the building and use of advanced and highly performing building materials [10,11]; 2) integration of passive systems and architectural design optimization concerning the characteristics that influence the most energy consumption, such as orientation and shape [12,13]. Nonetheless, the topic of building performance improvement is much broader, encompassing issues such as the home and workplace healthiness and safety [14,15,16], the comfort perceived by the users [17,18], and other aspects [19]. Actually, the attention paid by authors in the literature to the overall building performance increased earlier and faster than the focus on building energy efficiency, and is still growing stronger (Figure 1).
In this position paper, we argue that two somewhat niche topics—whether the focus is on energy efficiency or other aspects shaping the notion of building performance—are deeply intertwined with the issue of improving that performance, and thus, they deserve greater attention. The first topic—discussed below in Section 2—is hinged upon the notion of budget constraint, which plays a crucial role in the decision-making processes on the construction of new buildings or the renovation of existing ones, as it significantly affects the planning and execution stages, as well as the outcomes. The second topic discussed later in Section 3 is related to operating in critical scenarios, meaning dealing with building performance improvement while facing problematic situations, such as rapidly developing demographic phenomena and other anthropological changes, for instance, overcrowding due to fast population growth and recurrent natural disasters such like sea level rise and flash flooding due to climate change.
Economic issues are known to be tied to achievable levels of building performance [20]. The role played by economic parameters in shaping the viability of adopting efficiency measures is a case in point [21,22,23]. An additional case in point is represented by the examination of the financial incentives to push the adoption of efficiency measures, in addition to the rise and growth of innovative business models [24,25] to exploit those incentives in the building industry [26,27,28]. Another pertinent example is given in the studies dealing with the appraisal of the cost premium [29,30] and the price premium [31,32] of highly efficient buildings compared to conventional ones [33,34,35]. Nonetheless, the comparative analysis of the profitability of investing in high-performance constructions—whether performed through well-known cost-benefit or life-cycle cost models [36,37,38], or even novel economic and multi-criteria models [39,40]—often misses considering a second feasibility dimension, namely, the ability to meet a given budget constraint.
The early literature on the topic explored a variety of market failures and barriers—such as imperfect and asymmetric information, bounded rationality, split incentives, transaction costs, and more [41,42,43]—that hinder the adoption of state-of-the-art and high-performance solutions in buildings. While the actual occurrence of all these barriers is disputed [44,45,46], consumers' and firms' spending ability is recognized as a barrier itself [47,48]. There is an inherent conflict - apparent and yet still partly neglected - between the substantial costs required to get high-performance buildings and the limited ability to incur capital expenditures by property owners and other investors (Figure 2). A budget constraint is seldom included in the evaluation of performance optimization measures to be adopted in new [49,50] and existing buildings [51]. Its consideration is largely connected with the use of analytical models derived from the life-cycle costing approach and the cost-optimal methodology [52,53]. It is additionally linked to the planning of maintenance and renovation actions of building elements according to their deterioration function in a couple of research papers [54,55], as well as used among the inputs in investment decision optimization tools concerning retrofit measures in multiple buildings in another couple of studies [56,57,58].
There is a case for arguing that the research on the investments meant to improve building energy efficiency—and building performance, more broadly—has been focused primarily in Western economies and developed countries [59]. Thus, it has predominantly advanced in the EU and US contexts [60] with a few other additional areas, following the adoption and implementation of targeted policies, codes, and regulations in those countries, as also shown by the International Energy Agency in its 2018 report (Figure 3). Only recently, the literature reported studies of efficiency and performance in the least-developed countries. Such studies are still limited to a small number [61,62].
One of the issues with that lies in the lack of representativeness [63]. Western economies and developed countries hardly provide a comprehensive representation of the various situations the majority of the world's population faces, both in terms of rapidly evolving demographic phenomena— or other anthropological changes—and recurring natural disasters. We refer to them as critical scenarios. On the demographic and anthropological side, they include exponential population growth, fast rural-to-urban migration resulting in intensive land-use changes, overcrowding of urban areas, and other migratory movements with related shifts in needs and wants, tastes, and preferences [64,65,66]. On the environmental side, they also include sea level rise, flash flooding, drought, overheating, and desertification due to ongoing climate change, which represents a source of substantial risk for urban areas [67,68,69,70].
Since many of the above-mentioned disruptive phenomena are bound to occur in developing and underdeveloped countries [71,72,73], the dynamic interplay between budget constraints and critical scenarios looks like an interesting field of study. From a normative analysis perspective, what strategies and tactics should be adopted to cope with limitations on spending power while simultaneously dealing with challenging situations? Also, from a positive analysis perspective, what actual actions do the affected people, households, and firms put into play? How much do critical scenarios worsen the burden of budget constraints, especially in large urban areas and in developing countries? Thus, how much does exposure to critical scenarios exacerbate budget constraints? How do budget constraints in critical scenarios interact with medium-to long-run policy goals as far as building performance is concerned? These are just a few instances of the research questions populating this field of inquiry.
In the near future, we expect more and more studies to address the above research issues and, perhaps, other related research topics so as to start shedding light on this under-explored topic.
This paper is meant as the opening of the special issue "Budget constraints in critical scenarios: challenges to improving building performance" in the journal AIMS Energy. Please see: https://www.aimspress.com/aimse/article/6744/special-articles.
The authors declare no conflicts of interest.
[1] |
Esparza J (2013) What has 30 years of HIV research taught us? Vaccines 1: 513-526. doi: 10.3390/vaccines1040513
![]() |
[2] | Van Regenmortel MHV, Andrieu J-M, Dimitrov DS, et al. (2014) Paradigm Changes and the Future of HIV Vaccine Research: A Summary of a Workshop Held in Baltimore on 20 November 2013. J AIDS Clin Res 5: 3. |
[3] |
Burton DR (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2: 706-713. doi: 10.1038/nri891
![]() |
[4] | Van Regenmortel MHV (2014) An outdated notion of antibody specificity is one of the major detrimental assumptions of the structure-based reverse vaccinology paradigm, which prevented it from developing an effective HIV-1 vaccine. Front Immunol 5: 593. doi: 10.3389/fimmun.1014.00593. |
[5] | Dimitrov DS (2010) Therapeutic antibodies, vaccines and antibodyomes. MAbs 2: 347-356. |
[6] | Van Regenmortel MHV (2012) Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol 3: 194. |
[7] |
Richards FF, Konigsberg WH, Rosenstein RW, et al. (1975) On the specificity of antibodies. Science 187: 130-137. doi: 10.1126/science.46122
![]() |
[8] |
Van Regenmortel MHV (2014) Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit 27: 627-639. doi: 10.1002/jmr.2394
![]() |
[9] | Vijh-Warrier S, Pinter A, Honnen WJ, et al. (1996) Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J Virol 70: 4466-4475. |
[10] | Li A, Katinger H, Posner MR, et al. (1998) Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol 72: 3235-3240. |
[11] | Mascola JR, Louder MK, VanCott TC, et al. (1997) Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 71: 7198-7206. |
[12] |
Li A, Baba TW, Sodroski J, et al. (1997) Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses 13: 647-656. doi: 10.1089/aid.1997.13.647
![]() |
[13] |
Mascola JR, Haynes BF (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254: 225-244. doi: 10.1111/imr.12075
![]() |
[14] |
Nabel GJ, Kwong PD, Mascola JR (2011) Progress in the rational design of an AIDS vaccine. Phil Trans Roy Soc London B Biol Sci 366: 2759-2765. doi: 10.1098/rstb.2011.0096
![]() |
[15] | Schiller J, Chackerian B (2014) Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PloS Pathog 10: e1004254. |
[16] |
Wardemann H, Yurasov S, Schaefer A, et al. (2003) Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377. doi: 10.1126/science.1086907
![]() |
[17] |
Verkoczy L, Diaz M (2014) Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS 9: 224-234. doi: 10.1097/COH.0000000000000049
![]() |
[18] |
Poignard P, Moulard M, Golez E, et al. (2003) Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and non neutralizing antibodies. J Virol 77: 353-365. doi: 10.1128/JVI.77.1.353-365.2003
![]() |
[19] |
Moore PL, Crooks ET, Porter L, et al. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80: 2515-2528. doi: 10.1128/JVI.80.5.2515-2528.2006
![]() |
[20] |
Liu J, Bartesaghi A, Borgnia MJ, et al. (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113. doi: 10.1038/nature07159
![]() |
[21] |
Schief WR, Ban YE, Stamatatos L (2009) Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 4: 431-440. doi: 10.1097/COH.0b013e32832e6184
![]() |
[22] | Van Regenmortel MHV (1966) Plant virus serology. Adv Virus Res 12: 207-271. |
[23] |
Pancera M, McLellan JS, Wu X, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84: 8098-8110. doi: 10.1128/JVI.00966-10
![]() |
[24] |
Van Regenmortel MHV (1992) The conformational specificity of viral epitopes. FEMS Microbiol Lett 100: 483-487. doi: 10.1111/j.1574-6968.1992.tb14081.x
![]() |
[25] |
McElrath MJ, Haynes BF (2010) Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554. doi: 10.1016/j.immuni.2010.09.011
![]() |
[26] |
Burton DR, Desrosiers RC, Doms R, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236. doi: 10.1038/ni0304-233
![]() |
[27] |
Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Ann Rev Immunol 31: 705-42. doi: 10.1146/annurev-immunol-032712-095916
![]() |
[28] |
Walker LM, Phogat SK, Chan-Hui PY, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289. doi: 10.1126/science.1178746
![]() |
[29] |
Zhou T, Georgiev I, Wu X et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817. doi: 10.1126/science.1192819
![]() |
[30] | Sattentau QJ, McMichael AJ (2010) New templates for HIV-1 antibody-based vaccine design. F1000 Biol.Rep. 2: 60. |
[31] |
Lewis GK (2010) Challenges of antibody-mediated protection against HIV-1. Exp Rev Vaccines 9: 683-687. doi: 10.1586/erv.10.70
![]() |
[32] | Yu L, Guan Y (2014) Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1. Front Immunol 5: 250. |
[33] |
Stanfield RL, Gorny MK, Williams C, et al. (2004) Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447- 52D. Structure 12: 193-204. doi: 10.1016/j.str.2004.01.003
![]() |
[34] |
Briney BS, Willis JR, Crowe JE (2012) Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE 7: e36750. doi: 10.1371/journal.pone.0036750
![]() |
[35] |
Ackerman M, Alter G (2013) Mapping the journey to an HIV vaccine. N Engl J Med 369: 389-391. doi: 10.1056/NEJMcibr1304437
![]() |
[36] |
Klasse PJ, Sanders RW, Cerutti A, et al. (2012) How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses 28: 1-15. doi: 10.1089/aid.2011.0053
![]() |
[37] |
Bunnik EM, van Gils MJ, Lobbrecht MS, et al. (2009) Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. Virology 390: 348-355. doi: 10.1016/j.virol.2009.05.028
![]() |
[38] |
Berzofsky JA (1985) Intrinsic and extrinsic factors in protein antigenic structure. Science 229: 932-940. doi: 10.1126/science.2410982
![]() |
[39] |
Kunik V, Ofran Y (2013) The indistinguishability of epitopes from protein surface is explained by the distinct binding preferences of each of the six antigen-binding loops. Protein Eng Des Sel 26: 599-609. doi: 10.1093/protein/gzt027
![]() |
[40] | Sela-Culang I, Kunik V, Ofran Y (2013) The structural basis of antibody-antigen recognition. Front Immunol 4: 302. |
[41] |
Van Regenmortel MHV (2011) Limitations to the structure-based design of HIV-1 vaccine immunogens. J Mol Recognit 24: 741-753. doi: 10.1002/jmr.1116
![]() |
[42] |
Van Regenmortel MHV (2012) Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch Virol 157: 1-20. doi: 10.1007/s00705-011-1145-2
![]() |
[43] |
Dimitrov JD, Pashov AD, Vassilev TL (2012) Antibody specificity what does it matter ? Adv Exp Biol Med 750: 213-226. doi: 10.1007/978-1-4614-3461-0_16
![]() |
[44] |
Notkins AL (2004) Polyreactivity of antibody molecules. Trends Immunol 25: 174-9. doi: 10.1016/j.it.2004.02.004
![]() |
[45] |
Wucherpfennig KW, Allen PM, Celada F, et al. (2007) Polyspecificity of T cell and B cell receptor recognition. Semin Immunol 19: 216-24. doi: 10.1016/j.smim.2007.02.012
![]() |
[46] |
Eisen HN, Chakraborty AK (2010) Evolving concepts of specificity inimmune reactions. Proc Natl Acad Sci USA 107: 22373-22380. doi: 10.1073/pnas.1012051108
![]() |
[47] |
Mariuzza RA (2006) Multiple paths to multispecificity. Immunity 24: 359-361. doi: 10.1016/j.immuni.2006.03.009
![]() |
[48] |
Bramwell VW, Perrie Y (2005) The rational design of vaccines. Drug Discov Today 10: 1527-1534. doi: 10.1016/S1359-6446(05)03600-7
![]() |
[49] |
Douek DC, Kwong PD, Nabel GJ (2006) The rational design of an AIDS vaccine. Cell 124: 677-681. doi: 10.1016/j.cell.2006.02.005
![]() |
[50] |
D'Argenio DA, Wilson CB (2010) A decade of vaccines: integrating immunology and vaccinology for rational vaccine design. Immunity 33: 437-440. doi: 10.1016/j.immuni.2010.10.011
![]() |
[51] |
Walker LM, Burton DR (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22: 358-366. doi: 10.1016/j.coi.2010.02.012
![]() |
[52] |
Burton DR (2010) Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci USA 107: 17859-17860. doi: 10.1073/pnas.1012923107
![]() |
[53] |
Van Regenmortel MHV (2007) The rational design of biological complexity: a deceptive metaphor. Proteomics 7: 965-975. doi: 10.1002/pmic.200600407
![]() |
[54] |
Kuntz ID (1992) Structure-based strategies for drug design and discovery. Science 257: 1078-1082. doi: 10.1126/science.257.5073.1078
![]() |
[55] |
Wu X, Yang ZY, Li Y, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861. doi: 10.1126/science.1187659
![]() |
[56] |
Diskin R, Scheid JF, Marcovecchio PM, et al. (2011) Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334: 1289-1293. doi: 10.1126/science.1213782
![]() |
[57] |
Correia B, Bates JT, Loomis RJ, et al. (2014) Proof of principle for epitope-focused vaccine design. Nature 507: 201-206. doi: 10.1038/nature12966
![]() |
[58] | Bunge M (2003) Philosophical Dictionary. Amherst, NY: Promotheus Books. |
[59] |
Karlsson-Hedestam GB, Fouchier RA, Phogat S, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155. doi: 10.1038/nrmicro1819
![]() |
[60] |
Haynes BF, Kelsoe G, Harrison SC, et al. (2012) B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotech 30: 423-433. doi: 10.1038/nbt.2197
![]() |
[61] |
Moore PL, Gray ES, Wibmer CK, et al. (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18: 1688-1692. doi: 10.1038/nm.2985
![]() |
[62] |
Klein F, Diskin R, Scheid JF, et al. (2013) Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153: 126-138. doi: 10.1016/j.cell.2013.03.018
![]() |
[63] |
Liao HX, Lynch R, Zhou T, et al. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-476. doi: 10.1038/nature12053
![]() |
[64] | Verkoczy L, Kelsoe G, Haynes BF, et al. (2014) HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog 10: e 1004073. |
[65] |
West AP Jr, Scharf L, Scheid JF, et al. (2014) Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156: 633-648. doi: 10.1016/j.cell.2014.01.052
![]() |
[66] |
Doria-Rose NA, Schramm CA, Gorman J, et al. (2014) Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509: 55-62. doi: 10.1038/nature13036
![]() |
[67] | Prabakaran P, Chen W, Dimitrov DS (2014) The antibody germline/maturation hypothesis, elicitation of broadly neutralizing antibodies against HIV-1 and cord blood IgM repertoires. Front Immunol 5: 398. |